Table of Content

1. Key Insights

2. Executive Summary of BRAF Mutated NSCLC

3. SWOT Analysis of BRAF Mutated NSCLC

4. BRAF NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country

5. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total Incident cases of BRAF Mutated NSCLC in the United States

8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total Incident cases of BRAF Mutated NSCLC in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total Incident cases of BRAF Mutated NSCLC in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total Incident cases of BRAF Mutated NSCLC in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total Incident cases of BRAF Mutated NSCLC in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total Incident cases of BRAF Mutated NSCLC in the United Kingdom

9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total Incident cases of BRAF Mutated NSCLC in Japan

10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of NSCLC

13. Key Endpoints in NSCLC Clinical Trials

14. Marketed Therapies

15. Key Cross
15.1. Tafinlar(Dabrafenib) in Combination with Mekinist(Trametinib): Novartis
15.1.1. Product Description
15.1.2. Regulatory Milestones
15.1.3. Other Developmental Activities
15.1.4. Pivotal Clinical Trials

16. Emerging Therapies
16.6. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
16.6.1. Product Description
16.6.2. Clinical Development
16.6.3. Safety and Efficacy
16.7. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
16.7.1. Product Description
16.7.2. Clinical Development

17. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
17.1. Key Findings
17.2. Market Outlook: 7MM

18. BRAF Mutation?Market Size
18.1. Total Market Size of BRAF NSCLC in the 7MM
18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM
18.3. United States Market Size
18.3.1. Total Market size of BRAF NSCLC in the United States
18.4. EU-5 Market Size
18.4.1. Germany Market Size
18.4.2. France Market Size
18.4.3. Italy Market Size
18.4.4. Spain Market Size
18.4.5. United Kingdom Market Size
18.5. Japan Market Size
18.5.1. Total Market size of BRAF NSCLC in Japan

20. Market Access and Reimbursement of BRAF Mutated NSCLC Therapies
21. Market Drivers of BRAF Mutated NSCLC
22. Market Barriers of BRAF Mutated NSCLC
23. Appendix
23.1. Bibliography
24. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight



List of Figures


Figure 1 BRAF NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)
Figure 46 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 47 Timeline Illustrating the Development of Targeted Therapies and Immunotherapies for the Treatment of NSCLC Over two decades
Figure 48 Immune Checkpoint Inhibitor
Figure 49 Unmet Needs
Figure 50 Market Size of BRAF NSCLC in the 7MM Countries in USD Million (2017–2030)
Figure 51 Market Size of BRAF NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 52 Market Size of BRAF NSCLC by therapies in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size of BRAF NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 54 Market Size of BRAF NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 55 Market Size of BRAF NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 56 Market Size of BRAF NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 57 Market Size of BRAF NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 58 Market Size of BRAF NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 59 Market Size of BRAF NSCLC by Therapies in Japan, in USD Millions (2017–2030)
Figure 60 Market Drivers
Figure 61 Market Barriers

 

List of Tables


Table 1 Summary of BRAF Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)
Table 34 Standard Treatment Options of NSCLC (Stage-wise)
Table 35 Summary of Recommendations (SEOM Clinical Guideline)
Table 36 Strength of Evidence
Table 37 Strength of Evidence
Table 38 Marketed Drugs Key Cross
Table 39 Vemurafenib Plus Cobimetinib, Clinical Trial Description, 2020
Table 40 Braftovi (encorafinib) + Mektovi (binimetinib), Clinical Trial Description, 2020
Table 41 Enfortumab vedotin, Clinical Trial Description, 2020
Table 42 7MM Market Size of BRAF NSCLC in USD Million (2017–2030)
Table 43 7MM Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 44 7MM Market Size of BRAF NSCLC by therapies, in USD Million (2017–2030)
Table 45 United States Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 46 United States Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 47 Germany Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 48 Germany Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 49 France Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 50 France Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 51 Italy Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 52 Italy Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 53 Spain Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 54 Spain Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 55 United Kingdom Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 56 United Kingdom Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 57 Japan Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 58 Japan Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 59 National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies